Takeda?s Exclusive Distribution of Pfizer Products in Japan
Osaka and Tokyo, Japan, June 18, 2012—Takeda Pharmaceutical Company Limited (“Takeda”) and Pfizer Japan Inc. (“Pfizer”) announced today that they have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products that it previously procured from Wyeth K.K. and currently distributes under an exclusive distribution agreement with Pfizer, and that Pfizer, the manufacturer of the products, will begin selling them thereafter. In addition, Takeda will continue to distribute the pneumococcus vaccine Prevenar® for infants and young children and hemophilia B drug BeneFIX® (generic name: nonacog alfa) after January 2013.
Aside from this exclusive distribution agreement, the two companies agreed in February 2011 to extend the term of co-promotion agreement of the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept), the marketing of which Takeda will continue.
Takeda and Pfizer will remain committed to the prevention and treatment of diseases by providing drugs that meet the needs of patients and medical professionals through their successful partnership.
The 13 products, the marketing of which by Takeda will terminate on December 31, 2012 and be commenced by Pfizer in January, 2013
Isovorin®, active folate Artane®, treatment for
parkinsonian syndrome
Amoxan®, treatment for depression Torisel®, anticancer
agent
Napageln®, transdermal antiinflammatory drug Photofrin®,
treatment for photodynamic therapy
Premarin®, conjugated estrogens Mylotarg®, anticancer
agent
Minomycin®, antibiotic Methotrexate®, folate metabolism
blocker
Rheumatrex®, treatment for rheumatoid arthritis
Leucovorin®, anti-folate metabolism blocker
Wypax®, minor tranquilizer
The Products which Takeda will continue to distribute after January, 2013
Prevenar®, pneumococcus vaccine for infants and young
children BeneFIX®, treatment for hemophilia B
Enbrel®, treatment for rheumatoid arthritis
*Any impact that the termination of this exclusive distribution
might have has been factored into Takeda’s outlook for
consolidated results for the fiscal year ending March 31, 2013,
which was announced on May 11, 2012.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company
with its main focus on pharmaceuticals. As the largest
pharmaceutical company in Japan and one of the global leaders of
the industry, Takeda is committed to strive towards better health
for patients worldwide through leading innovation in medicine.
Additional information about Takeda is available through its
corporate website, www.takeda.com.
About Pfizer
Pfizer, a world’s leading research-based pharmaceutical, is
focusing on research, development and manufacturing of medicines
for people and animals. We strive to support people’s
lifelong health and well-being and contribute to improving quality
of life through innovative and valuable products globally.
To learn more about our activities, please visit us at
www.pfizer.com < http://www.pfizer.com/ > (Pfizer Inc.) and
www.pfizer.co.jp < http://www.pfizer.co.jp/ > (Pfizer Japan
Inc.)
Posted: June 2012
